T
T

TVGN - Tevogen • Financials

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
0
-8
-
0%
L
-94
L
94
L
-8
-0
4
-8
0
0
-
-
12/2024
0
-53
-
0%
L
-7
L
1
L
-53
0
12
-53
0
0
-
-
12/2025
0
-26
-
0%
L
-8
L
5
L
-29
-0
12
-29
0
0
-
-

To see all financials—including updated, you must be Premium.